Antagonism of collagen-induced ECG changes in rats by a thromboxane synthetase inhibitor, CV-4151

Ten weeks old male Sprague-Dawley rats were used. One mg/kg of a calfskin type III collagen was injected into a tail vein under pentobarbital anesthesia, and the electrocardiogram (ECG) was recorded via leads I, II and III for 10 min. Abnormal ECG patterns, i.e., ST-T changes and incidence of arrhyt...

Full description

Saved in:
Bibliographic Details
Published inNihon yakurigaku zasshi Vol. 87; no. 4; p. 397
Main Authors Matsumura, H, Terashita, Z, Nishikawa, K, Imai, Y
Format Journal Article
LanguageJapanese
Published Japan 1986
Subjects
6-Ketoprostaglandin F1 alpha - blood
Animals
Anti-Arrhythmia Agents
Arrhythmias, Cardiac - prevention & control
Collagen - antagonists & inhibitors
Coronary Disease - chemically induced
Coronary Disease - drug therapy
Electrocardiography
Fatty Acids, Monounsaturated
Fatty Acids, Unsaturated - therapeutic use
Humans
Pyridines - therapeutic use
Rats
Rats, Inbred Strains
Thiophenes - therapeutic use
Thromboxane B2 - blood
Ticlopidine
Online AccessGet more information

Cover

More Information
Summary:Ten weeks old male Sprague-Dawley rats were used. One mg/kg of a calfskin type III collagen was injected into a tail vein under pentobarbital anesthesia, and the electrocardiogram (ECG) was recorded via leads I, II and III for 10 min. Abnormal ECG patterns, i.e., ST-T changes and incidence of arrhythmia, were shown after collagen injection, and some rats suffered cardiac arrest. Oral administration of (E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid (CV-4151), a thromboxane synthetase inhibitor, at the dose of 10 mg/kg two hr before the collagen injection made the ST-T changes small, and it reduced the incidence of cardiac arrest. The effect of CV-4151 was greater than that of 30 mg/kg of ticlopidine with the same type of treatment. Neither CV-4151 nor ticlopidine had any affect on collagen-induced decreases in the blood platelet count. However, plasma thromboxane (TX) B2 level in the CV-4151-treated group was very low in comparison with those in both the control and ticlopidine-treated groups at 10 min after the collagen injection. These findings indicate that TXA2 may contribute, at least partly, to the collagen-induced ECG changes and indicate that CV-4151 might be a favorable agent for the prevention of TXA2-mediated cardiac ischemia.
ISSN:0015-5691
DOI:10.1254/fpj.87.397